Kunming Longjin Pharmaceutical Co., Ltd.
SZSE:002750.SZ
9.92 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 86.623 | 122.966 | 702.519 | 254.027 | 275.292 | 335.985 | 304.448 | 223.631 | 181.428 | 187.402 | 178.853 | 182.133 | 148.558 |
| Cost of Revenue
| 33.882 | 25.571 | 484.246 | 51.349 | 48.264 | 33.146 | 34.009 | 45.032 | 62.99 | 57.77 | 47.557 | 50.68 | 34.327 |
| Gross Profit
| 52.741 | 97.395 | 218.273 | 202.677 | 227.028 | 302.839 | 270.439 | 178.6 | 118.438 | 129.633 | 131.296 | 131.453 | 114.231 |
| Gross Profit Ratio
| 0.609 | 0.792 | 0.311 | 0.798 | 0.825 | 0.901 | 0.888 | 0.799 | 0.653 | 0.692 | 0.734 | 0.722 | 0.769 |
| Reseach & Development Expenses
| 22.221 | 24.95 | 19.587 | 19.599 | 20.683 | 32.298 | 27.205 | 21.082 | 9.536 | 9.464 | 8.157 | 7.566 | 7.397 |
| General & Administrative Expenses
| 9.809 | 9.031 | 8.299 | 6.445 | 8.784 | 8.997 | 10.306 | 11.124 | 11.717 | 8.762 | 9.449 | 9.899 | 5.96 |
| Selling & Marketing Expenses
| 64.729 | 80.534 | 165.124 | 157.981 | 182.148 | 242.608 | 182.806 | 58.474 | 14.633 | 16.892 | 16.717 | 13.705 | 14.656 |
| SG&A
| 74.538 | 89.564 | 173.423 | 164.427 | 190.932 | 251.605 | 193.111 | 69.599 | 26.35 | 25.655 | 26.166 | 23.604 | 20.616 |
| Other Expenses
| 0.996 | 17.079 | 26.71 | 14.705 | 14.115 | -1.018 | -1 | 4.884 | 7.828 | 2.305 | 3.709 | 4.044 | 0.944 |
| Operating Expenses
| 114.528 | 131.593 | 219.719 | 198.731 | 225.73 | 298.792 | 234.76 | 113.389 | 56.992 | 55.294 | 45.41 | 40.389 | 38.191 |
| Operating Income
| -81.935 | -34.199 | 6.933 | 8.643 | 35.1 | 16.695 | 41.804 | 97.14 | 64.926 | 73.374 | 86.072 | 114.155 | 80.716 |
| Operating Income Ratio
| -0.946 | -0.278 | 0.01 | 0.034 | 0.127 | 0.05 | 0.137 | 0.434 | 0.358 | 0.392 | 0.481 | 0.627 | 0.543 |
| Total Other Income Expenses Net
| -20.455 | -34.53 | -12.497 | -1.33 | -57.488 | 11.63 | 5.125 | 36.813 | 11.198 | 1.34 | 3.896 | 27.135 | 5.62 |
| Income Before Tax
| -82.242 | -68.729 | -5.564 | 7.313 | -22.389 | 15.678 | 40.804 | 102.024 | 72.644 | 75.678 | 89.781 | 118.199 | 81.66 |
| Income Before Tax Ratio
| -0.949 | -0.559 | -0.008 | 0.029 | -0.081 | 0.047 | 0.134 | 0.456 | 0.4 | 0.404 | 0.502 | 0.649 | 0.55 |
| Income Tax Expense
| 2.02 | 4.799 | 1.896 | -0.442 | 1.548 | 1.85 | 5.644 | 11.023 | 10.881 | 12.105 | 14.726 | 17.999 | 12 |
| Net Income
| -70.941 | -73.528 | -7.46 | 7.754 | -23.937 | 13.87 | 35.16 | 91.034 | 61.801 | 63.573 | 75.056 | 100.2 | 69.66 |
| Net Income Ratio
| -0.819 | -0.598 | -0.011 | 0.031 | -0.087 | 0.041 | 0.115 | 0.407 | 0.341 | 0.339 | 0.42 | 0.55 | 0.469 |
| EPS
| -0.18 | -0.18 | -0.019 | 0.019 | -0.06 | 0.035 | 0.088 | 0.23 | 0.16 | 0.21 | 0.25 | 0.33 | 0.23 |
| EPS Diluted
| -0.18 | -0.18 | -0.019 | 0.019 | -0.06 | 0.035 | 0.088 | 0.23 | 0.16 | 0.21 | 0.25 | 0.33 | 0.23 |
| EBITDA
| -4.925 | -8.349 | 37.77 | 37.63 | 61.295 | 26.691 | 61.497 | 124.722 | 96.082 | 99.295 | 89.94 | 120.814 | 85.551 |
| EBITDA Ratio
| -0.057 | -0.068 | 0.054 | 0.148 | 0.223 | 0.079 | 0.202 | 0.558 | 0.53 | 0.53 | 0.503 | 0.663 | 0.576 |